A stratified precision medicine trial targeting α2a-adrenergic receptor agonism as a treatment for the cognitive biotype of depression

Although clinicians now have an expanding range of effective treatments for major depressive disorder, selecting the right treatment for an individual patient remains largely a process of trial and error. Precision psychiatry seeks to address this challenge by integrating objective biological information with clinical assessment to guide more personalised treatment selection.

Leanne Williams will present a stratified precision medicine approach that prospectively identifies patients with a cognitive biotype of depression who are specifically likely to benefit from α2a-adrenergic receptor agonism. She will describe findings from a prospective study demonstrating that guanfacine improved cognitive control circuit function, cognitive performance and clinical outcomes in patients identified with this neuroscience-defined subtype. Importantly, the findings support treatment specificity for the cognitive biotype rather than a general biomarker of depression or a non-specific treatment response.

Williams will then describe how these findings have informed the ongoing ACE-D trial, which extends this work by prospectively evaluating neuroscience-guided treatment selection within routine clinical care. Rather than asking whether brain measures predict depression, this programme asks whether they can identify patients who are specifically likely to benefit from a treatment with a defined neurobiological mechanism.

The lecture will conclude by considering how biologically informed stratification can complement clinical expertise, moving the field beyond biomarker discovery towards prospective validation of mechanism-based treatment selection and the practical implementation of precision psychiatry in routine care.